Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database by Keiko Miyazato, Hiroshi Ohtsu, Akihiko Shimomura, Naohiro Yonemoto, Chikako Shimizu, Kazuhiro Sase, Shinichiro Ueda

Subjects: Get full text

Metastatic Extramammary Paget’s Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature by Peter Barth, Essel Dulaimi Al-Saleem, Kristin W. Edwards, Sherri Z. Millis, Yu-Ning Wong, Daniel M. Geynisman

“…We report a case of a complete response to single agent trastuzumab in a hemodialysis patient with metastatic Her2/neu overexpressed EMPD of the scrotum. …”
Get full text

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

“…Abstract DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). …”
Get full text

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments by Amit Verma, Vikas Pandey, Catherine Sherry, Taylor Humphrey, Christopher James, Kailie Matteson, Jason T. Smith, Alena Rudkouskaya, Xavier Intes, Margarida Barroso

Subjects: Get full text

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy by Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie

“…The patient received three cycles of pembrolizumab plus trastuzumab and chemotherapy preoperatively and underwent radical surgery on November 22, 2022.ConclusionPatients with HER-2-positive locally advanced GEJ cancers received PD-1 immunotherapy combined with trastuzumab and neoadjuvant chemotherapy and achieved a complete pathological response. …”
Get full text

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study by Fei Wang, Yongjiu Wang, Bin Xiong, Zhenlin Yang, Jingfen Wang, Yumin Yao, Lixiang Yu, Qinye Fu, Liang Li, Qiang Zhang, Chao Zheng, Shuya Huang, Liyuan Liu, Chun Liu, Huaibo Sun, Beibei Mao, Dong-Xu Liu, Zhigang Yu

“…Abstract The potential benefits of pyrotinib for patients with trastuzumab-insensitive, HER2-positive early-stage breast cancer remain unclear. …”
Get full text

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

Subjects: Get full text

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence by Ji‐Hua Shi, Wen‐Zhi Guo, Yang Jin, Hua-Peng Zhang, Chun Pang, Jie Li, Pål‐Dag Line, Shui‐Jun Zhang

Subjects: Get full text

Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments by Belluzzi L, Martinelli G, Medici B, Farina A, Martinelli E, Canino F, Caggia F, Molinaro A, Barbolini M, Tamburrano F, Moscetti L, Piacentini F, Dominici M, Omarini C

Subjects: Get full text

A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation ther... by Jing Yang, Meng-Yun Zhou, Bo Yu, Qing Lin, Yuan Yao, Hua-Ling Wu, Qi-Wei Zhu, Ming Ye, Hua-Ying Xie, Jian-Wei Wu, Gang Cai, Rong Cai, Wei-Xiang Qi, Jia-Yi Chen, Lu Cao

“…Purpose: This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT). …”
Get full text

Role of Fcγ receptors in HER2-targeted breast cancer therapy by Hope S Rugo, Antonino Musolino, William J Gradishar, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram

“…This results in differential FcγR-mediated activities associated with differential therapeutic outcomes across multiple clinical settings, from early stage to metastatic disease, in patients with HER2+ breast cancer treated with the anti-HER2 mAb trastuzumab. Trastuzumab has, nonetheless, revolutionized HER2+ breast cancer treatment, and several HER2-directed mAbs have been developed using Fc glyco-engineering or Fc protein-engineering to enhance FcγR-mediated functions. …”
Get full text

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer by Hanghang Ma, Jianbin Li

“…Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options after ADCs. …”
Get full text

Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch) by Dina Labib, Mark Haykowsky, Emer Sonnex, John R. Mackey, Richard B. Thompson, D. Ian Paterson, Edith Pituskin

“…Abstract Background This study investigates the long-term cardiac effects of trastuzumab-based chemotherapy in early breast cancer (EBC) survivors. …”
Get full text

Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate by Tobias M. Prass, Patrick Garidel, Lars V. Schäfer, Michaela Blech

“…Model systems composed of two marketed therapeutic IgG1 monoclonal antibodies with identical Fc domain sequences, trastuzumab and omalizumab, were investigated with commonly used excipients arginine, glutamate, and equimolar arginine/glutamate mixtures. …”
Get full text

Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations by Joel Heisler, Daniel Kovner, Saeed Izadi, Jonathan Zarzar, Paul J. Carter

“…The low viscosity of trastuzumab (8.6 cP) was unchanged or increased by [Formula: see text]2-fold by the different Fc variants. …”
Get full text

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma by Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini

“…Moreover, both cVLP-HER2 + cVLP-PCSK9 and cVLP-HER2 alone induced anti-HER2 antibodies able to inhibit the 3D growth of human HER2 +  +  + BT-474 and trastuzumab-resistant BT-474 C5 cells. Strikingly, antibodies elicited by the combined vaccination were more effective than those elicited by the cVLP-HER2 vaccine alone in the inhibition of trastuzumab-resistant C5 cells. …”
Get full text

Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer by Solmaz AghaAmiri, Jo Simien, Alastair M. Thompson, Julie Voss, Sukhen C. Ghosh, Servando Hernandez Vargas, Sarah Kim, Ali Azhdarinia, Hop S. Tran Cao

“…Here, we examine two approved anti-HER2 monoclonal antibodies (mAbs), trastuzumab and pertuzumab, as potential candidates for the development of immunoconjugates for fluorescence-guided surgery (FGS). …”
Get full text

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation by Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet Sağıroğlu, Ömer Uyanık, Sabri Barutca

“…Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. …”
Get full text

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization by Cathy B. Moelans, Roel A. de Weger, Marja T.M. van Blokland, Chantal Ezendam, Sabrina Elshof, Marcel G. J. Tilanus, Paul J. van Diest

“…Background: Assessment of HER-2/neu status in invasive breast cancer is crucial to establish eligibility for trastuzumab and taxane based chemotherapy. Next to immunohistochemistry (IHC) to evaluate protein overexpression, a second line gene amplification test is required for cases with equivocal protein expression. …”
Get full text